Novartis India will hold a meeting of the Board of Directors of the Company on 10 May 2024.Powered by Capital Market - Live News

The Board of Novartis India at its meeting held on 17 February 2024 took note of the communication received from Novartis AG, Holding Company & Promoter, regarding their intention to conduct a strategic review to unlock value of their shareholding in the Company. After some deliberations, the Board agreed to support Novartis AG, as may be required, in evaluating their strategic options. Powered by Capital Market - Live News

The Board of Novartis India at its meeting held on 17 February 2024 has approved the appointment of Gira Sardesai (DIN: 02610502), as an Additional Director (designated as Non-Executive and Independent Director) with effect from 31 March 2024. The Board also took note of cessation of Jai Hiremath (DIN: 00062203) as an Independent Director of the company on completion of his second and final term with effect from 31 March 2024. The Board has also appointed Christopher Snook (DIN: 00369790), as Non-Executive and Non-Independent Director for a period of 4 (four) consecutive years with effect from 31 March 2024.Powered by Capital Market - Live News

Net profit of Novartis India rose 249.15% to Rs 26.57 crore in the quarter ended December 2023 as against Rs 7.61 crore during the previous quarter ended December 2022. Sales rose 5.45% to Rs 84.54 crore in the quarter ended December 2023 as against Rs 80.17 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales84.5480.17 5 OPM %23.399.53 - PBDT41.5715.54 168 PBT41.3114.24 190 NP26.577.61 249 Powered by Capital Market - Live News

Novartis India will hold a meeting of the Board of Directors of the Company on 25 January 2024.Powered by Capital Market - Live News